Epidemiology, clinical manifestations and efficiency of different methods of treatment of acromegaly according to the United Russian Registry of Patients with Pituitary Tumors

BACKGROUND: The registry is the main source of information about patients with acromegaly for assessing the quality of medical care, effectiveness of treatment, determining the compliance of real clinical practice with existing standards and patient management protocols.

AIMS: To evaluate epidemiological, demographic and clinical characteristics of acromegaly in Russian Federation and effectiveness of treatment modalities.

MATERIALS AND METHODS: The object of the study was the database of the united Russian registry of patients with pituitary tumors with specific analysis of patients with acromegaly only. We analyzed the data of 4114 patients with acromegaly stored on the online system in February 2019.

RESULTS: Based on the data 32% of patients had complete clinical and laboratory remission of acromegaly; the percentage of patients with no remission was 68%, among them 22.5% had significant improvements in clinical symptoms and a decrease in growth hormone (GH) and insulin-like growth factor-1 (IGF-1) without IGF-1 normalization. The average age of patients at the onset of the disease was 42.7 years and at diagnosis – 45.8 years. The ratio of men to women was 1:2.6. In patients with acromegaly hypopituitarism was registered in 14.7% of cases and among them hypothyroidism (66%) and hypogonadism (52%) were registered more often. Among other complications the leading were diabetes mellitus (15.7%) and acromegalic arthropathy (15%). The proportion of patients receiving neurosurgical treatment increased from 35.7% to 49.6% in 2012–2019; the portion of patients undergoing radiation therapy decreased significantly from 17.7% in 2012 to 0.8% in 2019. Remission was achieved in 40.47% after neurosurgery and 28.95% after medical treatment as a first line therapy p<0.01. The number of patients receiving medical treatment at the time of the study was 1209. Among them 51% of patients treated with long-acting lanreotide and 24% receiving long-acting octreotide achieved remission (p<0.0001)

CONCLUSIONS: The remission rate of acromegaly remains suboptimal despite increased surgical activity, which corresponds to global trends. Long-acting lanreotide was significantly superior versus long-acting octreotide in the rate of acromegaly remission, which does not correspond with clinical trials.

acromegaly, IGF1, registries, epidemiology, treatment, somatostatin analogs, lanreotide

1. Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4–9. doi: 10.1007/s11102-016-0754-x.

2. gks.ru [интернет]. Федеральная служба государственной статистики. Росстат [доступ от 07.06.2019]. Доступ по ссылке http://www.gks.ru/.

3. Bex M, Abs R, T’Sjoen G, et al. AcroBel – the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur J Endocrinol. 2007;157(4):399–409. doi: 10.1530/EJE-07-0358.

4. Sesmilo G, Gaztambide S, Venegas E, et al. Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary. 2013;16(1):115–121. doi: 10.1007/s11102-012-0384-x.

5. Agustsson TT, Baldvinsdottir T, Jonasson JG, et al. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol. 2015;173(5):655–664. doi: 10.1530/EJE-15-0189.

6. Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, et al. The Mexican Acromegaly Registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab. 2016;101(11):3997–4004. doi: 10.1210/jc.2016-1937.

7. Maione L, Chanson P. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101264. doi: 10.1016/j.beem.2019.02.001.

8. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liège, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769–4775. doi: 10.1210/jc.2006-1668.

9. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377–382. doi: 10.1111/j.1365-2265.2009.03667.x.

10. Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992–2007. J Clin Endocrinol Metab. 2010;95(9):4268–4275. doi: 10.1210/jc.2010-0537.

11. Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013;16(4):545–553. doi: 10.1007/s11102-012-0454-0.

12. Maione L, Brue T, Beckers A, et al. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol. 2017;176(5):645–655. doi: 10.1530/EJE-16-1064.

13. Mestron A, Webb S, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151(4):439–446. doi: 10.1530/eje.0.1510439.

14. Schöfl C, Franz H, Grussendorf M, et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol. 2013;168(1):39–47. doi: 10.1530/EJE-12-0602.

15. Bello MO, Garla VV. Gigantism and acromegaly [Internet]. Treasure Island, USA, FL: StatPearls Publishing; 2020 [cited 2019 Jun 3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538261/.

16. Anagnostis P, Efstathiadou ZA, Polyzos SA, et al. Acromegaly: presentation, morbidity and treatment outcomes at a single centre. Int J Clin Pract. 2011;65(8):896–902. doi: 10.1111/j.1742-1241.2011.02682.x.

17. Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167(2):189–198. doi: 10.1530/EJE-12-0084.

18. Vallette S, Ezzat S, Chik C, et al. Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin Endocrinol (Oxf). 2013;79(1):79–85. doi: 10.1111/cen.12112.

19. Kwon O, Song YD, Kim SY, et al. Nationwide survey of acromegaly in South Korea. Clin Endocrinol (Oxf). 2013;78(4):577–585. doi: 10.1111/cen.12020.

20. Mercieca C, Gruppetta M, Vassallo J. Epidemiology, treatment trends and outcomes of acromegaly. Eur J Intern Med. 2012;23(8):e206–e207. doi: 10.1016/j.ejim.2012.07.010.

21. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667–674. doi: 10.1210/jc.2003-031199.

22. Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–561. doi: 10.1038/s41574-018-0058-5.

23. Дедов И.И., Молитвословова Н.Н., Рожинская Л.Я., Мельниченко Г.А. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения акромегалии // Проблемы эндокринологии. 2013. Т.59. №6. С. 4–18. [Dedov II, Molitvoslovova NN, Rozhinskaia LI, Mel’nichenko GA. Russian Association of Endocrinologists National Practice Guidelines (clinical signs, diagnosis, differential diagnosis, treatment). Acromegaly. Problems of Endocrinology. 2013;59(6):4–18. (In Russ).] doi: 10.14341/probl20135964-18.

24. Gadelha MR, Wildemberg LE, Bronstein MD, et al. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017;20(1):100–108. doi: 10.1007/s11102-017-0791-0.

25. Giustina A, Mazziotti G, Cannavò S, et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J Clin Endocrinol Metab. 2017;102(7):2454–2464. doi: 10.1210/jc.2017-00142.

26. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374–378. doi: 10.1210/jcem.83.2.4556.

27. Vilar L, Czepielewsk MA, Naves LA, et al. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr Pract. 2007;13(4):396–402. doi: 10.4158/EP.13.4.396.

28. Marazuela M, Ramos-Leví A, Sampedro-Núñez M, Bernabeu I. Cabergoline treatment in acromegaly: pros. Endocrine. 2014;46(2):215–219. doi: 10.1007/s12020-014-0206-1.